Yasuyuki Kinjo

Dr. Yasuyuki Kinjo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in International Journal of Surgery
Verified
Journal Article
Closed access
YKYasuyuki Kinjo
Yasuyuki Kinjo
TKTomoko Kurita
Tomoko Kurita
YFYoshihisa Fujino
Yoshihisa Fujino
TKTakashi Kawasaki
Takashi Kawasaki
KYKiyoshi Yoshino
Kiyoshi Yoshino
THToru Hachisuga
Toru Hachisuga
Ultrasound-guided nerve blocks are effective; however, their use in the abdominal wall is reportedly associated with a risk of abdominal organ injury. Laparoscopic-guided nerve blocks are thought to be safer than ultrasound-guided nerve blocks. We evaluated the safety and effectiveness of the laparoscopic-guided rectus sheath block (LGRSB) for umbilical incisions after gynecologic laparoscopy. A single-center, prospective, randomized controlled trial of 210 women who underwent gynecologic laparoscopy was performed at a university teaching hospital in Japan. The intervention group underwent the LGRSB with ropivacaine hydrochloride at the end of laparoscopy under general anesthesia and received regular care. The control group received only regular care without a field block. The postoperative pain score (PPS) was recorded at 6 and 12 h and 1, 2, and 3 days postoperatively. The PPS and use of postoperative analgesics (loxoprofen, diclofenac, and pentazocine) were recorded by the floor nurses, who were blinded to the patients' data. In total, 107 women in the intervention group and 101 women in the control group were analyzed. No adverse events were encountered throughout this study. There was no evidence of differences in the PPS or use of perioperative opioids and postoperative analgesics. The LGRSB for umbilical incisions after laparoscopic gynecology was easy and safe. However, this method did not significantly reduce the PPS at rest or during coughing in all postoperative conditions after gynecologic laparoscopy compared with the control.

17 May 2024 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MSMao Sekimata
Mao Sekimata
YKYasuyuki Kinjo
Yasuyuki Kinjo
ATAtsushi Tohyama
Atsushi Tohyama
MMMidori Murakami
Midori Murakami
SHSayumi Hashiwaki
Sayumi Hashiwaki
KYKiyoshi Yoshino
Kiyoshi Yoshino
Cytokine release syndrome (CRS) is a systemic inflammatory condition caused by an excessive immune response and cytokine overproduction. CRS is a life‑threatening condition that is often associated with chimeric antigen receptor T‑cell therapy. Despite the increased use of immune checkpoint inhibitors (ICIs), ICI‑induced CRS remains rare. The present study describes a case of CRS that occurred after the administration of ICIs for recurrent adenocarcinoma of the uterine cervix. A 49‑year‑old woman received paclitaxel, carboplatin and pembrolizumab for recurrent cervical adenocarcinoma. On day 27 of the third cycle, the patient was admitted with a fever and suspected pyelonephritis. The following day, hypotension, upper respiratory symptoms and myalgia of the extremities were noted, and the left ventricular ejection fraction (LVEF) was decreased to 20%. Multiorgan failure (MOF) occurred, and the patient received ventilator support and continuous hemodiafiltration. Rhabdomyolysis, pancreatitis, erythema multiforme and enteritis were observed. CRS was diagnosed based on elevated ferritin and IL‑6 levels. Steroid pulse therapy was administered; however, the MOF did not improve and the anti‑IL‑6‑receptor monoclonal antibody tocilizumab (TOC) was administered. Subsequently, the LVEF improved to 50%, and the patient was removed from the ventilator on day 4 and from the continuous hemodiafiltration unit on day 6 after TOC administration. The patient was discharged on day 21. In conclusion, considering that ICI‑induced CRS is a rare but severe complication, fever and other systemic conditions following ICI administration should be monitored.

13 May 2024 in Environment International
Verified
Journal Article
Open access
YKYasuyuki Kinjo
Yasuyuki Kinjo
ESEiji Shibata
Eiji Shibata
DADavid J. Askew
David J. Askew
RTRie Tanaka
Rie Tanaka
RSReiko Suga
Reiko Suga
KYKiyoshi Yoshino
Kiyoshi Yoshino
Lifelong health is dependent on prenatal growth and development, influenced by the placental intrauterine environment. Charged with dual functions--exchange of oxygen and nutrients as well as a barrier against toxins--the placenta itself is susceptible to environmental exposure to heavy metals. To examine the use of placenta weight as a biomarker for heavy metal exposure using a large Japanese cohort of pregnant women. The placenta weight, as a biomarker of exposure to heavy metals (cadmium, lead, and mercury), was investigated using data from the Japan Environment and Children's Study (2011-2014). Selenium and manganese were included as factors directly affecting fetal growth or heavy metal toxicity. Maternal blood samples collected in the second or third trimester were used to measure heavy metal concentrations. The association between maternal blood metal concentrations and placenta weight was explored by applying Z scores and multivariable logistic regression analysis and classifying participants into quartiles (Q1, Q2, Q3, and Q4) according to metal concentrations. This study included a total of 73,005 singleton pregnant women who delivered via live births and met the inclusion criteria. The median heavy metal concentrations in the maternal whole blood were 0.662 ng/g cadmium, 5.85 ng/g lead, 3.61 ng/g mercury, 168 ng/g selenium, and 15.3 ng/g manganese. Regression analysis revealed a significant correlation between placenta weight Z scores and maternal blood metal concentrations: cadmium, 0.0660 (standard error = 0.0074, p < 0.001); selenium, -0.3137 (standard error = 0.0276, p < 0.001); and manganese, 0.1483 (standard error = 0.0110, p < 0.001). This study provides a robust examination of the association between heavy metal exposure and placenta weight. Cadmium and manganese showed a positive correlation with significant differences, whereas selenium showed a negative correlation. Essential elements notably affect placenta weight differently. No significant association was noted between lead or mercury and placenta weight.

19 April 2022 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
YKYasuyuki Kinjo
Yasuyuki Kinjo
YMYusuke Matsuura
Yusuke Matsuura
TOTakayuki Ohguri
Takayuki Ohguri
YAYoko Aoyama
Yoko Aoyama
MMMidori Murakami
Midori Murakami
KYKiyoshi Yoshino
Kiyoshi Yoshino
There is currently controversy regarding the criteria for low and intermediate risk of cervical cancer (CC) after surgery. In the present study, the Gynecology Oncology Group (GOG) score was used to detect intermediate risk. Adjuvant radiotherapy was applied in the case of a GOG score >120. The present study aimed to evaluate the validity of the recurrence risk classification using the GOG score for stage IB‑IIA node‑negative CC. All cases of stage IB‑IIA node‑negative CC who underwent radical surgery between February 2007 and December 2015 were retrospectively reviewed. The GOG scores were determined from clinical and pathological findings and accordingly, subjects were divided into 4 groups: A, ≤40; B, >40 and ≤70; C, >70 and ≤120; and D, >120. Overall survival (OS) and recurrence‑free survival (RFS) curves were generated using the Kaplan‑Meier method. The log‑rank test produced an estimated P‑value by comparing the OS and RFS of group A (low‑score group) with those of others. The present study included 61 patients (mean age, 47.82 years; age range, 22‑76 years) and the median follow‑up was 79 (39‑149) months. Of these, 60 patients were observed for at least 60 months. During the follow‑up period, the OS and RFS rates of group C were 94.7 and 84.2%, respectively, while those of group D were 100 and 91.7%, respectively; the OS and RFS of groups A and B were 100%. Log‑rank tests for all OS and RFS indicated no significant differences compared to group A. It was indicated that a GOG score ≤70 does not require adjuvant therapy; however, a GOG score >70 requires consideration of adjuvant therapy based on the risk factors which constitute the score.

10 February 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
HHHiroshi Harada
Hiroshi Harada
THToru Hachisuga
Toru Hachisuga
YHYoshikazu Harada
Yoshikazu Harada
MSMami Shibahara
Mami Shibahara
MMMidori Murakami
Midori Murakami
KYKiyoshi Yoshino
Kiyoshi Yoshino
Background: The immunoreactive (IR) subtype is one of the subtypes of high-grade serous ovarian carcinoma (HGSOC) with intra-tumoral lymphocytic infiltration. A positive prognostic correlation between IR subtype and R0 + optimal surgery has been reported. This study investigates the prognostic significance of tumor-infiltrating lymphocytes (TILs) in the suboptimal surgery group of HGSOCs. Methods: After reviewing 318 malignant ovarian tumors detected in our database between 2000 and 2017, 74 HGSOCs with supplemental p53 immunostaining were selected. Differences in progression-free survival (PFS) and overall survival (OS) between the two groups of the IR subtype and the other subtypes were investigated. Based on pathological findings, HGSOCs were divided into two groups: those with or without abundant TILs. Results: Abundant TILs were detected in 17 cases of HGSOC (22.9%). Clinicopathological characteristics including age, CA125, FIGO stage, and residual disease did not show significant differences between the two groups. Lymph node metastasis was more common in the IR subtype group (p = 0.04). In the suboptimal surgery group, the 5-year PFS and OS (Kaplan–Meier estimates) in cases with (n = 10) or without (n = 21) abundant TILs were 10% and 0% (p = 0.097) and 70% and 28.5% (p = 0.012), respectively. The median time (range) to OS in cases with or without abundant TILs were 58 (34–81) months and 39 (22–55) months, respectively. Multivariate analysis in OS showed significant differences in TILs. Conclusions: Abundant intra-tumoral lymphocytic infiltration is an independent and favorable prognostic indicator for the suboptimal surgery group in HGSOCs and is associated with treatment response via cancer immunity.

13 December 2024 in Case Reports in Oncology
Verified
Journal Article
Open access
SHShota Higami
Shota Higami
YKYasuyuki Kinjo
Yasuyuki Kinjo
MSMao Sekimata
Mao Sekimata
YYYuta Yoshimatsu
Yuta Yoshimatsu
YMYu Murakami
Yu Murakami
KYKiyoshi Yoshino
Kiyoshi Yoshino
Introduction: Pseudoaneurysm following gynecologic cancer surgery is a rare complication that can become fatal when it ruptures. Common sites of pseudoaneurysms are the external iliac artery, hypogastric artery, and aorta, which are located around the lymphadenectomy site. There are no previous reports of ruptured inferior epigastric (IEA) artery pseudoaneurysms after gynecologic cancer surgery. We report a case of intraperitoneal bleeding induced by a ruptured IEA pseudoaneurysm following interval debulking surgery for stage IVB ovarian cancer. Case Presentation: The patient underwent total abdominal simple hysterectomy, bilateral salpingo-oophorectomy, omentectomy, ileocolic resection, and peritonectomy around the ileocecal area after 5 cycles of neoadjuvant chemotherapy. The patient suddenly presented with loss of consciousness and reduced blood pressure on postoperative day 20. Her blood hemoglobin levels also decreased. Contrast-enhanced computed tomography revealed a pseudoaneurysm in the right IEA. There were no signs of extravasation from the pseudoaneurysm; however, bloody ascites was observed in the abdominal cavity. A ruptured IEA pseudoaneurysm was suspected, and coil embolization was immediately performed. Her symptoms abated soon after coil embolization, and she remained symptom-free during the 8 months of postoperative follow-up. Conclusion: Awareness of this rare complication is clinically important for its early detection and treatment.